Baidu
map

Hepatology:替诺福韦酯治疗青少年HBV感染安全有效

2012-12-28 Hepatology 互联网 20819004

近期公布的一项临床试验结果表明,成人用抗病毒药物替诺福韦酯(tenofovir DF)可安全有效地治疗青少年HBV感染。研究表明,替诺福韦酯对HBV的抑制率达89%,该结果发表于今年12月的《肝病学》(Hepatology)杂志上,该杂志隶属于美国肝病研究协会。 慢性HBV感染给全球健康带来巨大的负担,共有3.5亿人感染HBV,其中有60万人死于这种疾病。疾病控制中心(CDC)估计,超过100万

近期公布的一项临床试验结果表明,成人用抗病毒药物替诺福韦酯(tenofovir DF)可安全有效地治疗青少年HBV感染。研究表明,替诺福韦酯对HBV的抑制率达89%,该结果发表于今年12月的《肝病学》(Hepatology)杂志上,该杂志隶属于美国肝病研究协会。

慢性HBV感染给全球健康带来巨大的负担,共有3.5亿人感染HBV,其中有60万人死于这种疾病。疾病控制中心(CDC)估计,超过100万美国人感染慢性HBV,大多数都是在幼年时期感染。医学证据表明,大约90%患者感染于婴儿时期,感染于1至4岁之间的患者中超过半数发展为慢性HBV;于幼年时期感染的成人患者中有25%发展为肝硬化或肝癌。华盛顿州西雅图市儿童医院胃肠病学和肝病学科主负责人KarenMurray说:“感染慢性HBV的儿童发展为严重肝脏疾病的风险较高,并且致死率也高。替诺福韦酯能够非常有效地治疗成人慢性HBV感染,我们的试验旨在评估这种药物在青少年身上的安全性和有效性。”

本项随机双盲安慰剂对照临床试验共纳入了101名年龄在12至17周岁之间的青少年患者。该试验持续72周,在试验过程中,受试者被随机分配,其中52名青少年接受每日300mg剂量的替诺福韦酯,剩下的患者接受安慰剂。此项临床试验的主要终点是抗病毒药物的病毒应答能力对HBV的抑制效果。在实验开始前,91%的受试者为HBeAg阳性,85%既往接受过乙肝治疗。研究人员发现,替诺福韦酯治疗组89%的受试患者出现病毒学应答,而安慰剂组所有患者均未出现HBV抑制。在治疗组中,替诺福韦酯能够有效抑制HBV增殖并使谷丙转氨酶恢复到正常范围,这种疗效在既往有或无乙肝治疗史的患者身上均得到验证。没有报道出现安全性问题,实验人群亦未出现耐药现象。

Murray博士称:“替诺福韦酯治疗青少年HBV感染表现出良好的耐受性和有效性,试验证明了替诺福韦对青少年慢性HBV的病情控制是有益的。”他还透露,将有一项为期两年的开放性试验研究对替诺福韦DF的持续性病毒学应答和安全性作进一步研究。

该杂志也刊登了加州大学旧金山分校的Philip Rosenthal博士撰写的一篇评论性文章,对应采取何种手段才能改变那些慢性HBV感染儿童发展为肝病和肝癌的进程提出疑问。Rosenthal说:“不久前,治疗HBV的药物还很有限,但如今我们很欣喜地发现被批准用于儿童和青少年的治疗药物的增加。然而Murray等人的研究只限于青少年人群,有关替诺福韦酯用于更小年龄儿童的进一步研究还正在进行中。”

替诺福韦酯相关的拓展阅读:

DOI: 10.1002/hep.25818
PMC:
PMID:

Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B

Karen F. Murray1,¶,*, Leszek Szenborn2, Jacek Wysocki3, Stephen Rossi4, Amoreena C. Corsa4, Phillip Dinh4, John McHutchison4, Phillip S. Pang4, Luminita M. Luminos5, Malgorzata Pawlowska6, Jacek Mizerski7

Tenofovir disoproxil fumarate (DF) is highly effective for the suppression of hepatitis B virus (HBV) in chronically infected adults. This study evaluated the safety and efficacy of tenofovir DF in adolescents with chronic hepatitis B (CHB). In this double-blind, placebo-controlled trial, adolescents 12 to <18 years of age with CHB were randomized to tenofovir DF 300 mg (n = 52) or placebo (n = 54) once daily for 72 weeks. The primary endpoint was virologic response (HBV DNA <400 copies/mL) at week 72. One hundred six patients were enrolled; 101 patients completed 72 weeks of treatment. At baseline, 91% of patients were hepatitis B e antigen–positive and 85% had prior exposure to HBV therapy. A virologic response was observed in 89% (46/52) of patients who received tenofovir DF and 0% (0/54) of patients who received placebo (P < 0.001). Treatment response was not affected by prior HBV treatment. Furthermore, no resistance to tenofovir DF developed through week 72. Among patients with an alanine aminotransferase (ALT) level greater than the upper limit of normal at baseline, normalization of ALT occurred in 74% of patients receiving tenofovir DF and 31% of patients receiving placebo (P < 0.001). The rate of grade 3/4 adverse events was higher among patients treated with placebo (24%) than patients treated with tenofovir DF (10%). No patients met the safety endpoint of a 6% decrease in spine bone mineral density at week 72. Conclusion: Tenofovir DF therapy in HBV-infected adolescents was well tolerated and highly effective at suppressing HBV DNA and normalizing ALT values in both treatment-naïve adolescents and those with prior exposure to HBV therapy.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1836572, encodeId=e82518365e285, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Fri Apr 26 22:33:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426519, encodeId=11e61426519e6, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428605, encodeId=2f381428605cd, content=<a href='/topic/show?id=9a0f60359a7' target=_blank style='color:#2F92EE;'>#替诺福韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60359, encryptionId=9a0f60359a7, topicName=替诺福韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be144108328, createdName=yhj-time, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462179, encodeId=0ac114621e9d9, content=<a href='/topic/show?id=b97885350d' target=_blank style='color:#2F92EE;'>#HBV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8535, encryptionId=b97885350d, topicName=HBV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33ed6479538, createdName=Tommy1951, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596747, encodeId=16d61596e479f, content=<a href='/topic/show?id=b41a603616e' target=_blank style='color:#2F92EE;'>#替诺福韦酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60361, encryptionId=b41a603616e, topicName=替诺福韦酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49fd18409827, createdName=Tommy1955, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=)]
    2013-04-26 klivis
  2. [GetPortalCommentsPageByObjectIdResponse(id=1836572, encodeId=e82518365e285, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Fri Apr 26 22:33:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426519, encodeId=11e61426519e6, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428605, encodeId=2f381428605cd, content=<a href='/topic/show?id=9a0f60359a7' target=_blank style='color:#2F92EE;'>#替诺福韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60359, encryptionId=9a0f60359a7, topicName=替诺福韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be144108328, createdName=yhj-time, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462179, encodeId=0ac114621e9d9, content=<a href='/topic/show?id=b97885350d' target=_blank style='color:#2F92EE;'>#HBV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8535, encryptionId=b97885350d, topicName=HBV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33ed6479538, createdName=Tommy1951, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596747, encodeId=16d61596e479f, content=<a href='/topic/show?id=b41a603616e' target=_blank style='color:#2F92EE;'>#替诺福韦酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60361, encryptionId=b41a603616e, topicName=替诺福韦酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49fd18409827, createdName=Tommy1955, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=)]
    2012-12-30 gwc384
  3. [GetPortalCommentsPageByObjectIdResponse(id=1836572, encodeId=e82518365e285, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Fri Apr 26 22:33:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426519, encodeId=11e61426519e6, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428605, encodeId=2f381428605cd, content=<a href='/topic/show?id=9a0f60359a7' target=_blank style='color:#2F92EE;'>#替诺福韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60359, encryptionId=9a0f60359a7, topicName=替诺福韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be144108328, createdName=yhj-time, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462179, encodeId=0ac114621e9d9, content=<a href='/topic/show?id=b97885350d' target=_blank style='color:#2F92EE;'>#HBV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8535, encryptionId=b97885350d, topicName=HBV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33ed6479538, createdName=Tommy1951, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596747, encodeId=16d61596e479f, content=<a href='/topic/show?id=b41a603616e' target=_blank style='color:#2F92EE;'>#替诺福韦酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60361, encryptionId=b41a603616e, topicName=替诺福韦酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49fd18409827, createdName=Tommy1955, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1836572, encodeId=e82518365e285, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Fri Apr 26 22:33:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426519, encodeId=11e61426519e6, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428605, encodeId=2f381428605cd, content=<a href='/topic/show?id=9a0f60359a7' target=_blank style='color:#2F92EE;'>#替诺福韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60359, encryptionId=9a0f60359a7, topicName=替诺福韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be144108328, createdName=yhj-time, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462179, encodeId=0ac114621e9d9, content=<a href='/topic/show?id=b97885350d' target=_blank style='color:#2F92EE;'>#HBV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8535, encryptionId=b97885350d, topicName=HBV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33ed6479538, createdName=Tommy1951, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596747, encodeId=16d61596e479f, content=<a href='/topic/show?id=b41a603616e' target=_blank style='color:#2F92EE;'>#替诺福韦酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60361, encryptionId=b41a603616e, topicName=替诺福韦酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49fd18409827, createdName=Tommy1955, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1836572, encodeId=e82518365e285, content=<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8524, encryptionId=f9d08524be, topicName=HBV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Fri Apr 26 22:33:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426519, encodeId=11e61426519e6, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1428605, encodeId=2f381428605cd, content=<a href='/topic/show?id=9a0f60359a7' target=_blank style='color:#2F92EE;'>#替诺福韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60359, encryptionId=9a0f60359a7, topicName=替诺福韦)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be144108328, createdName=yhj-time, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1462179, encodeId=0ac114621e9d9, content=<a href='/topic/show?id=b97885350d' target=_blank style='color:#2F92EE;'>#HBV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8535, encryptionId=b97885350d, topicName=HBV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33ed6479538, createdName=Tommy1951, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596747, encodeId=16d61596e479f, content=<a href='/topic/show?id=b41a603616e' target=_blank style='color:#2F92EE;'>#替诺福韦酯#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60361, encryptionId=b41a603616e, topicName=替诺福韦酯)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=49fd18409827, createdName=Tommy1955, createdTime=Sun Dec 30 08:33:00 CST 2012, time=2012-12-30, status=1, ipAttribution=)]

相关资讯

Hepatology:变异体在晚期转移性肝癌中起重要作用

来自武汉大学医学院、武汉大学人民医院以及江西赣南医学院的研究人员近日在新研究中证实KIAA0101变异体1(KIAA0101 tv1)在晚期转移性肝癌中起重要作用,通过调控p53功能促进了肝癌细胞生存。相关论文发表在国际著名肝脏疾病杂志Hepatology上。 武汉大学医学院的朱帆(Fan Zhu)为这篇论文的通讯作者。其研究方向是“逆转录病毒感染引发精神分裂症的分子机制研究”以及“HB

Hepatology:美国HBV感染者死亡原因分析

HBV是一种严重的全球性感染性疾病,可以导致肝硬化,肿瘤及肝功能失代偿,严重的会导致死亡。虽然全球某些有关于对HBV患者生存的长期报道(台湾,意大利),但是其他地区的生存统计仍空缺。日前,来自美国加州Kaiser Permanente(凯萨医疗机构)胃肠病科的Jean-Luc Szpakowski和Lue-Yen Tucker进行了有关美国HBV患者的一项自然病程队列研究,研究结果在线发表于Hep

Hepatology:抑癌因子控制了非酒精性脂肪性肝炎的发展

近日,来自日本庆应义塾大学医学院的研究人员发现,在人类及老鼠体内,p53/p66Shc介导的信号促进了非酒精性脂肪性肝炎(NASH)的发展。相关研究成果于5月28日在线发表在Journal of Hepatology上。 p53基因是一种抑癌基因,是细胞生长周期中的负调节因子,与细胞周期的调控、DNA修复、细胞分化、细胞凋亡等重要的生物学功能有关。p53基因的突变(缺失)是人类肿瘤的常见事件,与

Hepatology:CXCL5介导中性粒细胞浸润促进肝癌转移

趋化因子是能使细胞发生趋化运动的小分子细胞因子,分子量多在8-14kDa之间。趋化因子与趋化因子受体结合后传递多种细胞信息。CXCL5是一个小分子类型的分泌蛋白,属于趋型趋化因子家族成员。近来,CXCL5与癌症发生发展的相关证据已经有很多。 最近,为了研究CXCL5在肝细胞癌的生长、侵袭和预后中的作用,研究人员研究了具有不同转移性能的人肝癌细胞系以及919例肝癌患者中CXCL5的mRNA和蛋白水

Baidu
map
Baidu
map
Baidu
map